Email updates

Keep up to date with the latest news and content from Experimental Hematology and Oncology and BioMed Central.

Open Access Review

The role of BCL11B in hematological malignancy

Xin Huang1, Xin Du1 and Yangqiu Li23*

Author Affiliations

1 Department of Hematology, Guangdong General Hospital (Guangdong Academy of Medical Sciences), Guangzhou, 510080, China

2 Institute of Hematology, Medical College, Jinan University, Guangzhou, 510632, China

3 Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, 510632, China

For all author emails, please log on.

Experimental Hematology & Oncology 2012, 1:22  doi:10.1186/2162-3619-1-22

Published: 22 August 2012

Abstract

The B-cell leukemia/lymphoma 11B (BCL11B) gene is a member of the BCL family which plays a crucial role in the development, proliferation, differentiation and subsequent survival of T cells. BCL11B gene alterations are related to malignant T cell transformation that occurs in hematological malignancies. Remarkably, the BCL11B gene is responsible for the regulation of the apoptotic process and cell proliferation. This review summarizes current data and knowledge concerning the alteration of BCL11B in hematological malignancies and its role as a potential target for therapies directed against T cell malignancies.

Keywords:
BCL11B; Altered expression; Hematological malignancy; Apoptosis; Targeted therapy